Today in Science: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today in Science.

Press releases published on June 18, 2026

As Communities Deploy Opioid Settlement Funds, APT Foundation Emphasizes the Role of Public Education and Outreach
Shaping Luminescence in 3D: Advanced Fabrication of YAG:Ce³⁺ Microstructures
Money Simpler Launches Multi-Strategy AI Quantitative Trading Platform for Digital Asset Investors
PubHive Launches Multiple Citation Matcher to Streamline Scientific Literature and Evidence Workflows
Hi*Ball Energy erobert Großbritannien und wird zum Vorreiter des neuen „Clean Energy“-Trends
Hi*Ball Energy fait son entrée au Royaume-Uni et redéfinit les codes de la boisson énergisante
Annual General Meeting Statement
VivaTech Tech for Change winner MS4ALL uses its "virtual microscope" deeptech to speed up forever chemicals' degradation
C1 Announces Enterprise-Managed Authorization Support to Drive Secure AI Transformation for the Enterprise
Teva Releases Q2 2026 Aide Memoire
Alamos Gold Provides Operational Update Across Canadian Operations
Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
JellyFil Supplement Claims Evaluated: Documenting Jelly Fil Gummies Ingredients Investigation for Consumer Safety
Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET
Global ECG Patch and Holter Monitor Market Size/Share Worth USD 3.92 Billion by 2035 at a 9.2% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Odysight.ai® Clarifies its Disciplined Approach to Capital Raising
BlockchAIn Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares of Common Stock
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Memento Medicines Launches with $93 Million Series A Financing to advance Tie2 Agonist and VEGF Inhibitor Bispecific Antibody Therapy for Retinal Diseases 

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Today in Science

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.